Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 1.00 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | NOS1 | P29475 | 1/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.53 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.49 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29350303 | 1.00 | NCF1 (1.00) | NCF1PRMT6ALDH1A1HTTKDM4E | |
| SCHEMBL11196105 | 0.91 | NCF1 (0.83) | NCF1PRMT6ALDH1A1HTTKDM4E | |
| Benzylamine SCHEMBL27789840 | 0.88 | NCF1 (0.78) | NCF1PRMT6ALDH1A1HTTKDM4E | |
| SCHEMBL113089 | 0.85 | NCF1 (0.74) | NCF1PRMT6ALDH1A1HPGDNOS1 | |
| SCHEMBL3719689 | 0.85 | NCF1 (0.73) | NCF1PRMT6ALDH1A1HTTKDM4E | |
| SCHEMBL110832 | 0.84 | PRMT6 (1.00) | NCF1PRMT6ALDH1A1KDM4EHRH3 | |
| SCHEMBL30364132 | 0.84 | PRMT6 (0.93) | NCF1PRMT6ALDH1A1KDM4EHRH3 | |
| SCHEMBL23182936 | 0.83 | NCF1 (0.71) | NCF1PRMT6ALDH1A1HTTKDM4E | |
| SCHEMBL2249512 | 0.83 | NCF1 (0.71) | NCF1PRMT6ALDH1A1HTTKDM4E | |
| SCHEMBL22711383 | 0.83 | NCF1 (0.71) | NCF1PRMT6ALDH1A1HTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| US-20240150346-A1 | CLASS OF HETEROAROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | INNOVSTONE THERAPEUTICS LIMITED (CN) | 2024-05-09 | — | — | US | disclosed |
| CN-114805341-B | Aromatic heterocyclic compound, and preparation method and application thereof | 上海翊石医药科技有限公司 | 2023-12-08 | — | — | CN | disclosed |
| WO-2022161420-A1 | CLASS OF HETEROAROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翊石医药科技有限公司 | 2022-08-04 | — | — | WO | disclosed |
| CN-114805341-A | Aromatic heterocyclic compounds and preparation method and application thereof | 上海翊石医药科技有限公司 | 2022-07-29 | — | — | CN | disclosed |
| US-20210276988-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2021-09-09 | — | — | US | disclosed |
| US-10882851-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-20160257673-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2016-09-08 | — | — | US | disclosed |
| US-9259426-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-8809365-B2 | 1-substituted 2-azabicyclo [3.1.1] heptyl derivatives useful as nicotinic acetylcholine receptor modulators for treating neurologic disorders | UNIVERSITEIT GENT (BE) | 2014-08-19 | — | — | US | disclosed |
| US-20070105860-A1 | Biphenylcarboxylic Amide Derivatives as p38 Kinase Inhibitors | GLAXO GROUP LIMITED | 2007-05-10 | — | — | US | disclosed |
| US-7151118-B2 | Biphenylcarboxylic amide derivatives as p38-kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2006-12-19 | — | — | US | disclosed |
| US-20050038014-A1 | 5'-carbamoyl-1,1' biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2005-02-17 | — | — | US | disclosed |
| US-20050020540-A1 | Biphenylcarboxylic amide derivatives as p38-kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2005-01-27 | — | — | US | disclosed |
| EP-1436269-A1 | OXADIAZOLYL-BIPHENYLCARBOXAMIDES AND THEIR USE AS P38 KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-07-14 | — | — | EP | disclosed |
| EP-1436272-A1 | BIPHENYLCARBOXYLIC AMIDE DERIVATIVES AS P38 KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-07-14 | — | — | EP | disclosed |
| EP-1435942-A1 | 5'-CARBAMOYL-1,1'-BIPHENYL-4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003033483-A1 | BIPHENYLCARBOXYLIC AMIDE DERIVATIVES AS P38 KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-04-24 | — | — | WO | disclosed |
| WO-2003033482-A1 | OXADIAZOLYL-BIPHENYLCARBOXAMIDES AND THEIR USE AS P38 KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-04-24 | — | — | WO | disclosed |
| WO-2003032980-A1 | 5'-CARBAMOYL-1,1'-BIPHENYL-4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150346-A1 | CLASS OF HETEROAROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | TLR7, TLR1, TLR8 | NCF1 600/4885PRMT6 4449/4885ALDH1A1 1289/4885 |
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | NR3C1, NR3C2, NR4A1 | NCF1 1648/4885PRMT6 757/4885ALDH1A1 2743/4885 |
| US-20070105860-A1 | Biphenylcarboxylic Amide Derivatives as p38 Kinase Inhibitors | MAPK1, MAPKAPK2, MAPK3 | NCF1 1585/4885PRMT6 2765/4885ALDH1A1 880/4885 |
| US-20050038014-A1 | 5'-carbamoyl-1,1' biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors | MAPK1, MAP4K2, MAP3K1 | NCF1 1197/4885PRMT6 944/4885ALDH1A1 1075/4885 |
| US-20210276988-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | NR3C1, NR3C2, NR4A1 | NCF1 1648/4885PRMT6 757/4885ALDH1A1 2743/4885 |
| US-20050020540-A1 | Biphenylcarboxylic amide derivatives as p38-kinase inhibitors | MAPK1, MAPKAPK2, MAP3K1 | NCF1 3098/4885PRMT6 2982/4885ALDH1A1 1005/4885 |
| US-10882851-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | NR3C1, NR3C2, NR5A2 | NCF1 1388/4885PRMT6 797/4885ALDH1A1 3119/4885 |
| US-20160257673-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | NR3C1, NR3C2, NR5A2 | NCF1 1388/4885PRMT6 797/4885ALDH1A1 3119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.